Fenofibrate - Cipher Pharmaceuticals
Alternative Names: CIP-FENOFIBRATE; Fenomax; LipofenLatest Information Update: 02 Oct 2021
At a glance
- Originator Cipher Pharmaceuticals
- Class Antihyperlipidaemics; Benzophenones; Butyric acids; Fibric acid derivatives; Propionates; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Hypercholesterolaemia
Most Recent Events
- 25 Jul 2012 Fenofibrate - Cipher Pharmaceuticals is available for licensing in World (excluding Canada, USA) as of 25 Jul 2012.
- 04 Aug 2008 ProEthic Pharmaceuticals has been acquired by Kowa
- 03 Jun 2008 Oryx Pharmaceuticals has been acquired by Sepracor